MOTS-c: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข4 community protocols documented
- โขEvidence level: Anecdotal Reports
- โขBased on 40 community reports
- โข3 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Species Translation | All MOTS-c research is preclinical, conducted in mouse models. Key studies used IP injection at 5-15 mg/kg in mice. No human clinical trials have been completed. MOTS-c was discovered in 2015 by the Cohen lab at USC. | Community uses fixed doses of 5-15 mg per week via subcutaneous injection. The human equivalent dose from mouse IP data at 5 mg/kg would be approximately 0.4 mg/kg (28 mg for a 70 kg person), but community doses are generally in this range when accounting for less-than-daily dosing. | high MOTS-c has never been tested in humans. All protocols are extrapolated from mouse data. The exercise-mimetic properties observed in mice may not translate to human physiology. |
| Exercise Context | Mouse studies showed that MOTS-c improved exercise capacity in both young and aged mice, enhanced insulin sensitivity, and regulated metabolic homeostasis through AMPK activation. | Community members often time MOTS-c injections around exercise sessions, believing in synergistic effects. Some use it as an "exercise enhancement" peptide, though the original research suggests it mimics exercise rather than enhances it. | moderate The distinction between "exercise mimetic" and "exercise enhancer" is important. MOTS-c activates similar pathways to exercise, but whether it enhances the effects of concurrent exercise or is redundant is unknown. |
| WADA Status | MOTS-c is on the World Anti-Doping Agency (WADA) prohibited list under S4.4 as an AMPK activator (metabolic modulator). | Community members should be aware that MOTS-c is prohibited in competitive sports by WADA. Its use by athletes in competition would constitute a doping violation. | moderate The WADA ban reflects concern about the performance-enhancing potential of MOTS-c based on preclinical data, even though human performance effects are unproven. |
Compare these community approaches with published research findings.
Community Protocols
Standard Weekly Protocol
Popular- Route
- Subcutaneous
- Dose
- 5-10 mg
- Frequency
- 2-3 times weekly
- Duration
- 4-10 weeks
Most commonly reported protocol; split weekly dose across 2-3 injections, often timed around exercise
Weekly Single-Dose Protocol
Common- Route
- Subcutaneous
- Dose
- 10 mg
- Frequency
- Once weekly
- Duration
- Up to 10 weeks
Single weekly injection timed before endurance exercise for added mitochondrial benefit
Daily Low-Dose Protocol
Niche- Route
- Subcutaneous
- Dose
- 1 mg
- Frequency
- Once daily
- Duration
- 4-8 weeks
Daily microdosing approach for more consistent AMPK activation; less common due to injection frequency
Titration Protocol
Niche- Route
- Subcutaneous
- Dose
- 200 mcg starting, titrate to 1000 mcg
- Frequency
- Once daily
- Duration
- 10 weeks with staged titration
Conservative staged approach starting at 200 mcg and increasing by 200 mcg every 2 weeks
Stacking Patterns
MOTS-c + SS-31 Mitochondrial Stack
NicheDual mitochondrial peptide stack targeting AMPK signaling (MOTS-c) and cardiolipin stabilization (SS-31) for comprehensive mitochondrial optimization
MOTS-c + Humanin MDP Stack
NicheCombining two mitochondrial-derived peptides for metabolic regulation (MOTS-c) and cytoprotection (Humanin)
MOTS-c + CJC-1295/Ipamorelin Metabolic Stack
NicheMOTS-c for metabolic optimization combined with GH secretagogues for body composition and recovery effects
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 40+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|MOTS-c experience reports and dosing discussions(accessed 2026-02-16)
- Reddit r/longevity|MOTS-c mitochondrial peptide discussions(accessed 2026-02-16)
- Swolverine|MOTS-c for Beginners - Benefits, Dosage, Stacking, and Side Effects(accessed 2026-02-16)
- Jay Campbell|MOTS-c - The Exercise Replacement Peptide(accessed 2026-02-16)
- The Peptide Report|MOTS-c Protocols and Dosages(accessed 2026-02-16)
- Innerbody|MOTS-c Peptide benefits, safety, and buying advice(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for MOTS-c. The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
MOTS-c is a mitochondrial-derived peptide discovered in 2015 that has gained significant community interest due to its exercise-mimetic properties and metabolic benefits in mouse models. It is one of the newer peptides in the community toolkit and has generated particular interest among those focused on metabolic health, exercise enhancement, and anti-aging.
Understanding Protocol Divergence#
No Human Clinical Data#
The most critical consideration for MOTS-c community use is that no human clinical trials have been completed. All protocols are derived from mouse studies. MOTS-c was only discovered in 2015, making the research base relatively young. The exercise-mimetic effects observed in mice (improved insulin sensitivity, enhanced exercise capacity) may not translate directly to human physiology.
Exercise Mimetic vs. Exercise Enhancer#
An important nuance often lost in community discussions is the distinction between "exercise mimetic" and "exercise enhancer." MOTS-c activates pathways similar to those activated by exercise (primarily AMPK), but whether it enhances concurrent exercise or provides redundant signaling is unknown. Community wisdom generally favors combining MOTS-c with exercise rather than using it as a substitute.
Commonly Reported Outcomes#
Community members report the following effects from MOTS-c use:
- Energy and endurance: Some users report improved exercise endurance and subjective energy levels
- Body composition: Reports of fat loss, particularly visceral fat, though confounded by concurrent exercise and diet changes
- Recovery: Some users report improved post-exercise recovery
- Metabolic markers: A few users report improved fasting glucose or insulin sensitivity on blood work
- Subtle effects: Many users note that effects are gradual and require weeks of use to notice
Important Caveats#
- No human clinical trials have been completed
- MOTS-c is on the WADA prohibited list for competitive athletes
- The "exercise replacement" framing is misleading
- Reports of body composition changes are confounded by lifestyle factors
- Product quality and peptide identity verification are important for this relatively new compound
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About MOTS-c
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.